Neuroanatomical changes in early Parkinson's disease with mild cognitive impairment: a VBM study; the Parkinson's

Giulia Donzuso1, Roberto Monastero2, Calogero E Cicero1

  • 1Department of Surgical and Medical Sciences Advanced Technologies "G.F. Ingrassia", University of Catania, Via Santa Sofia 78, Catania, 95123, Italy.

Abstract

Insights

Brain atrophy in the frontal and cerebellar regions is linked to mild cognitive impairment in Parkinson's disease (PD). Early detection of this gray matter reduction may serve as a key biomarker for cognitive decline in PD patients.

Area of Science:

  • Neuroimaging
  • Neurology
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) is prevalent in Parkinson's disease (PD), but its pathological basis remains unclear.
  • Voxel-based morphometry (VBM) can assess regional brain atrophy and its correlation with cognitive function in early PD-MCI.

Purpose of the Study:

  • To investigate regional brain atrophy patterns in Parkinson's disease patients with mild cognitive impairment (PD-MCI).
  • To explore the relationship between gray matter volume and cognitive performance in early PD-MCI.

Main Methods:

  • 106 Parkinson's disease patients were recruited and underwent MRI and neuropsychological evaluations.
  • Patients were classified into PD with normal cognition (PD-NC) and PD-MCI groups, including an early PD subgroup (disease duration ≤ 2 years).
  • Voxel-based morphometry (VBM) was used to compare gray matter density between groups.

Main Results:

  • PD-MCI patients exhibited significant gray matter reduction in the frontal gyrus, precuneus, angular gyrus, temporal lobe, and cerebellum.
  • Early PD-MCI showed gray matter density reductions in the superior frontal gyrus and cerebellum.
  • Cognitive performance in Raven's tests, Stroop, and Barrage correlated with gray matter volumes in the frontal lobe and precuneus.

Conclusions:

  • Frontal and cerebellar atrophy are detectable even in early stages of Parkinson's disease.
  • These atrophic changes can serve as early indicators of cognitive impairment in PD.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.2K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
762
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.1K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
587